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284F abry disease (FD; OMIM entry number: 301500) is anX-linked lysosomal storage disorder caused by deﬁcientactivity of a-galactosidase A resulting in accumulation
of glycosphingolipids with terminal a-D-galactosyl residue,
particularly globotriaosylceramide (GL-3, Gb3, CTH) and
globotriaosylsphingosine (Lyso-GL-3, lyso-Gb3).1 These
lipids progressively accumulate in the circulation and in
virtually all cell types and organs, resulting in the develop-
ment of a multisystem disorder. Affected patients are at high
risk of developing a small-ﬁber neuropathy, progressive pro-
teinuric kidney disease, ﬁbrotic cardiac disease resulting in
rhythm and conduction disturbances, progressive hypertro-
phic cardiomyopathy, and mostly ischemic cerebrovascular
stroke.2 Though this disease is X-linked, both males and fe-
males are affected by it.
Although diagnosis and management of FD have markedly
improved over the years, the disease has no cure, and current
therapy is suboptimal.3 Our goal was to summarize the cur-
rent knowledge and knowledge gaps regarding screening,
diagnosis, and therapy, and to propose a research agenda to
resolve outstanding controversial issues.
SCREENING AND DIAGNOSIS
Clinical presentation and diagnostic testing
The clinical characteristics of FD are described in Table 1. The
diagnosis is established in males by a-galactosidase A–speciﬁc
activity that is below 25% to 30% of mean control in pe-
ripheral white blood cells.2,4–7 Alpha-galactosidase A activity
is somewhat predictive of classic or later-onset manifestations.
Classically affected hemizygotes have undetectable or very low
(#3%) enzymatic activity.2 As with many genetic diseases,
there is a wide phenotypic variability even among patients
with the same GLA mutation. A late-onset phenotype of FD
exists mainly with cardiac-variant disease forms.8 These pa-
tients present with typical disease in their ﬁfth or sixth decade
but often lack the early alerting clinical features of angio-
keratoma, acroparesthesia, corneal opacities, and sweating
abnormalities. Patients with milder variants typically haveKidney International (2017) 91, 284–293
Table 1 | Manifestations in Fabry disease
Childhood and adolescence (£16 years)
Acroparesthesia/pain crisis: chronic or episodic, burning sensation in
the palms of hands or soles of feet, exacerbated by temperature
changes, fever, stress, physical exercise, and alcohol
Angiokeratomas: small, raised, dark red spots that develop slowly and
can be found on the buttocks, genitalia, inner thighs, back, and oral
cavity
Ophthalmologic abnormalities: cornea verticillata (whorl-shaped
opacity), posterior subcapsular cataracts, tortuous vascular lesions
in the retina and conjunctiva, dilated vessels on upper lid margin
Sensorineural hearing loss
Hypohidrosis or anhidrosis
Increased albuminuria
History of nonspeciﬁc bowel disturbances
History of lethargy and fatigue
Early adulthood (17–30 years)
More extensive angiokeratomas
High albuminuria (>1g/24 hours)
Edema or lymphedema
Fever
Hypohidrosis or anhidrosis
Lymphadenopathy
Heat sensitivity
Diarrhea, abdominal pain
Cardiac: bradycardia, short PR interval, left ventricular hypertrophy,
conduction defects
Later adulthood (age > 30 years)
Heart disease: ﬁbrotic, left and right ventricular hypertrophy, heart
valve abnormalities and dysrhythmias, sudden cardiac death,
angina, diastolic heart failure, cardiac transplantation
Chronic kidney disease: including end-stage renal disease requiring
renal replacement therapy with dialysis or renal transplantation
Stroke or transient ischemic attacks
Deafness, of acute or chronic onset
R Schiffmann et al.: Fabry disease: a KDIGO conference report mee t ing repor tmissense GLA mutations and variable residual enzyme
activity. For example, the N215S mutation may have residual
enzyme activity in plasma and/or leucocytes close to the
normal range. One exception is a splice mutation common in
Taiwanese patients with FD who have 10% residual enzyme
activity and develop left ventricular hypertrophy in their
fourth or ﬁfth decade of life.4
In heterozygous females, random X-inactivation may
result in expression of a-galactosidase A activity in the plasma
or leucocytes within the normal range in up to 60% of
women.9 Sequencing of the GLA gene is necessary for a
diagnosis of FD in most females. In addition to point mu-
tations, frameshift mutations and small deletions within
exons and exon-intron boundaries, large deletions, and
intronic mutations have been described.2 The ﬁnding of
elevated globotriaosylceramide (Gb3) in relevant tissues
should be the ultimate requirement when confronted with
GLA variants of unknown signiﬁcance.10 Erroneous attribu-
tion of pathogenicity to a mutation may lead to a costly and
inappropriate use of speciﬁc therapy such as enzyme
replacement therapy (ERT) and a missed opportunity toKidney International (2017) 91, 284–293make the correct diagnosis. Where enzyme activity is low and
no mutation is found by Sanger sequencing of exons and
exon-intron boundaries, further investigations including
multiplex ligation-dependent probe ampliﬁcation analysis
and assessment of speciﬁc intronic mutations should be
performed.11
Substrate accumulation including Gb3and lyso-Gb3 may
occur in plasma and urine. While glycolipid urinalysis may be
helpful in attributing pathogenicity or phenotype, it may be
less useful in screening because increased urinary Gb3 has
been described in cohorts of patients with cardiac disease or
nephrotic syndrome without a diagnosis of FD.12
Screening strategies for Fabry disease
Based on recent newborn screening studies each including at
least 30,000 newborns, the prevalence of FD was found to be
markedly higher than previously expected with 1 in 3100
males reported in northwestern Italy,13 1 in 3000 males in
Austria, 1 in 1300 males in Taiwan, 1 in 7800 males in
Washington state (USA), and 1 in 1500 males in Missouri
(USA). Before these studies, the prevalence was expected to be
much lower: 1 in 117,000 in Australia,14 1 in 468,000 in the
Netherlands,15 and only 1 in 833,000 in Portugal.16
High-risk screening. Screening for stroke in the young has
shown deﬁnite FD in 0.5%,17 in 0.9% of the hypertensive
population with left ventricular hypertrophy,18 in 0.5% to 1%
of patients with idiopathic hypertrophic cardiomyopathy5,19
but 4% of males,20 and in 0.11% to 0.17% of dialysis
patients.21–23 Only 0.2% of unselected patients with common
heart disease have FD.12 Prevalence screening studies may
inadvertently indicate falsely higher prevalence due to benign
polymorphisms (e.g., D313Y).24,25
FD should be considered and tested in patients with
chronic kidney disease (CKD) with no deﬁnitive cause of
nephropathy and when no biopsy has been performed,
especially in familial cases. The difﬁculty in recognizing this
condition due to a highly variable and nonspeciﬁc phenotype,
lack of positive family history in at least 5% of cases, and a
low prevalence rate in many regions of the world signiﬁes that
many patients are diagnosed late or never diagnosed.26 This
situation can only be reversed by the introduction of wide-
spread screening of at-risk patients.
Family screening. The X-linked nature of FD inheritance
renders cascade screening of families efﬁcient and of high
diagnostic yield over on average 3 generations surrounding
an index case. All index patients should meet with a genetic
counselor or a physician to produce an informative family
tree and facilitate communication with predicted affected
family members so they may be referred to a medical
geneticist for genetic counseling and testing. Considering
the privacy of the index case is important and must be
weighed against the risk of delayed diagnosis in family
members.27
Many patients ﬁnd it valuable to discuss implications of
testing with a clinical geneticist and may wish to consider
preconception genetic diagnosis, prenatal testing, or postnatal285
Table 2 | Knowledge gaps and research recommendations
Screening and diagnosis
 Elucidate role of gene variants of uncertain signiﬁcance
 Investigate potential genotype–phenotype relations
 Determine when to initiate speciﬁc treatment as a function of GLA
mutation severity
 Ascertain response to speciﬁc therapy as a function of GLA mutation
severity
 Establish an independent, transparent, and freely accessible registry of
consenting FD patients including phenotype, genotype data, and full
annotation of phenotypes
 Evaluate utility of cardiology screening of patients with a short PR
interval
 Identify optimal screening tools
 Follow the outcome of FD newborn screening programs
 Elucidate role of skewed X-inactivation in heterozygotes
 Investigate the mechanism of organ injury in female patients
 Pursue the use of biomarkers for diagnosis
 Acquire better understanding of glycosphingolipid pathogenesis and
basic cellular pathology
Initiation of therapy
 Determine when to start treatment in asymptomatic or pauci-
symptomatic patients, females, with nonclassic disease
 Obtain expanded information on the natural history of FD in classic
female patients and nonclassic FD patients, and the effects of ERT in
these groups
 Undertake X-linked inactivation studies and early initiation of therapy in
females
Therapeutic regimens
 Establish criteria and biomarkers for dose individualization
 Evaluate combination therapy: substrate synthesis reduction combined
with ERT or with a pharmacological chaperone
 Develop standardized assessment of neutralizing antibodies and eval-
uate impact on treatment regimens – utilize experience from Pompe
disease interventions
Outcomes
 Deﬁne therapeutic failure. Does progression of FD while undergoing
ERT indicate therapeutic failure?
 Deﬁne long-term outcomes of different dosing schemes in different
patient populations
 Deﬁne very long-term outcomes of patients starting ERT in childhood,
both on clinical manifestations and glycolipid burden
(e.g., cardiomyocytes, podocytes, vascular smooth muscle cells)
 Ascertain impact of ERT on heart and central nervous system disease,
valvular abnormalities and aortic root dilatation, and lymphedema
 Identify outcome of ERT in nonclassic FD
 Understand pathophysiology of lung involvement and treatment with
ERT as well as the role of b2-agonists86,114
 Provide uniform description and categorization of study populations in
future reports on the efﬁcacy of therapy, including genotype, pheno-
type, sex, and age at initiation of therapy
 Conduct long-term outcome studies of (pediatric) patients who started
ERT when asymptomatic or paucisymptomatic
 Collect histologic evidence of ERT-induced clearance of Gb3 in long-
lived cells: vascular smooth muscle cells, cardiomyocytes, podocytes
 Conduct studies on the pathophysiology and treatment of gastroin-
testinal involvement and lymphedema
 Develop more sensitive patient-reported outcome measures
ERT, enzyme replacement therapy; FD, Fabry disease.
meet ing repor t R Schiffmann et al.: Fabry disease: a KDIGO conference reportdiagnosis. Diagnosis in a Fabry male has particular diagnostic
implications for his mother and daughters, who will all, in the
absence of new mutations or nonpaternity, have positive test
results. The risk of FD in any male or female offspring of a
woman with FD is 50%.27 Once a genetic diagnosis has been
made, patients should undergo a full clinical evaluation and
treatment as described in Supplementary Table S1.
Knowledge gaps and research recommendations
(Table 2). The true prevalence of FD is not known, but
future systematic screening for the disease in the general
population may help determine it. Another challenge is to
predict the pathogenicity of some GLA variants. Because
newborn screening for FD has effectively begun in certain
jurisdictions, future research must evaluate the ethical and
psychological ramiﬁcations of early diagnosis of a disorder
that may or may not manifest itself until years or decades
later.
ENZYME REPLACEMENT THERAPY
ERT with recombinant human a-galactosidase A (agalsidase)
is the only currently available therapy aimed at the etiology of
FD (Supplementary Table S2). Agalsidase-a and agalsidase-b
have been studied in clinical trials with different primary
endpoints, hampering comparison of effectiveness. However,
surrogate endpoints were evaluated on both enzymes in
placebo-controlled trials that led to regulatory approval
(Supplementary Table S3). These trials have reported on short
periods of ERT, with different clinical endpoints, predomi-
nantly in (male) typical patients. As FD is a rare chronic,
slowly progressive disease with a 4-decade natural history and
broad heterogeneous presentation, this evidence is incom-
plete. Extrapolating results to long-term patient management
or other Fabry populations is challenging. Based on ethical
and feasibility considerations, it is very unlikely that further
evidence from placebo-controlled trials will become available.
Additional knowledge is provided by case series and post-
marketing surveillance databases that, despite their limita-
tions, suggest that the earlier therapy is started, the better the
outcome may be. This observation is in accordance with the
hypothesis that glycolipid clearance is most therapeutically
effective before secondary, irreversible tissue injury has
occurred.
Initiation of ERT
Expert opinion-based recommendations on initiation and
cessation of ERT are available.28,29 However, there is no
scientiﬁc evidence as to the optimal age of ERT initiation.
Therefore, there are no uniform guidelines, and conditions
and age to start ERT differ in various countries. In general,
development of signs or symptoms related to FD is an indi-
cation to start ERT. For the kidney, this implies the devel-
opment of CKD (i.e., pathological albuminuria or decreased
glomerular ﬁltration rate [GFR]) or progressive decrease
in GFR) if ERT has not already been started earlier for
nonrenal manifestations such as pain.30 The beneﬁts of early
treatment, before irreversible tissue injury occurs, should be286balanced against the burden of biweekly infusions in very
young individuals. In a recent pediatric randomized
controlled trial (RCT), Fabry arteriopathy and segmental
effacement of podocyte foot processes were found in all
biopsied FD patients with normal GFR and urinary albumin-
to-creatinine ratio (UACR) < 30 mg/g,31 suggesting earlyKidney International (2017) 91, 284–293
R Schiffmann et al.: Fabry disease: a KDIGO conference report mee t ing repor trenal involvement and by inference an indication for initia-
tion of ERT before kidney injury, marked by proteinuria or
reduced GFR, become clinically apparent. There is lack of
agreement on cessation criteria.
Glycolipid deposits. Placebo-controlled RCTs in classic FD
have consistently shown that within 6 months, ERT reduces
plasma and urinary Gb3 and capillary endothelial Gb3
(Supplementary Table S3). Clearance of Gb3 in other slowly
dividing cells may take years. In young patients, there is some
limited evidence of a dose-dependent clearance of podocytes
over 5 years of follow-up.32 This ﬁnding has not yet been
established as an acceptable surrogate for beneﬁcial renal
therapeutic effect.
Kidney, cardiac, and cerebral disease. Overall, there is a
suggestion that ERT slows the progression of kidney
involvement in FD and results in reduction of hypertrophic
cardiomyopathy, especially when started prior to established
ﬁbrosis. However, there is no reduction in the rate of stroke
with ERT. Though there are limited data and only few
comparative studies, it is suggested that dose may have an
impact. Only 1 placebo-controlled study addressed the effect
of ERT (1.0 mg/kg/2 weeks agalsidase-b) on severe renal,
cardiac, or central nervous system events. A small decrease in
clinical events was observed after a prespeciﬁed correction for
imbalances at baseline (Supplementary Table S3).33 One
patient registry study shows a decline in clinical event rate
after the ﬁrst 6 months of agalsidase-b, but in general there is
no indication that the event rate on ERT is lower than the
natural history of the disease.34,35 The clinical event rate for
patients taking agalsidase-a has not been published, although
morbidity may be delayed in these patients.36 The observed
differences in ERT outcomes may be caused by the profound
clinical heterogeneity of studied patients (Supplementary
Table S3).
Proteinuria is a well-recognized factor associated with
progressive loss of kidney function in many forms of CKD.37
In the phase 3 trial with agalsidase-b, classic FD patients
presenting with <1.0 g/day (d) of proteinuria had stabiliza-
tion of their renal function during 5 years of follow-up.38 In
contrast, classic patients presenting with >1 g/d of protein-
uria, usually associated with ﬁbrosis and scarring in more
than half of the glomeruli on baseline renal biopsies, had
progressive loss of kidney function, many reaching CKD stage
5.38 These results have been extended with 10 years of follow-
up. The important factors related to progressive loss of kidney
function were age at which ERT was initiated and averaged
ratio of urinary protein to creatinine <0.5 g/g (<0.5 g/d, <50
mg/mmol) during the follow-up period.39,40 In those with
uncontrolled proteinuria or a reduced GFR (<60 ml/min/
1.73 m2), ERT alone does not seem to prevent further dete-
rioration of renal function.
The phase 3 follow-up results have been incorporated into
various treatment recommendations, with the suggestion that
ERT be withheld if there is clinical evidence of more severe
renal involvement as denoted by signiﬁcant proteinuria or
loss of kidney function. This recommendation does notKidney International (2017) 91, 284–293address the appreciable number of patients with FD who
present with pathological levels of albuminuria (>30 mg/g
albumin-to-creatinine ratio) and reduced kidney function at
initial evaluation,41 or the opportunity to initiate ERT before
overt organ damage develops.32,42,43 Renal biopsies are useful
in such cases to determine the severity of cellular injury (e.g.,
podocyte effacement) and organ damage (e.g., glomerular
sclerosis and ﬁbrosis; vascular smooth muscle hypertrophy
and arteriopathy) that can develop before clinical signs of
kidney involvement become apparent.
ERT may improve left ventricular hypertrophy if no
ﬁbrosis is present at baseline,44,45 but cardiac ﬁbrosis will
progress during ERT, especially if severe (i.e., greater than 3
segments). Left ventricular hypertrophy reduction is not a
proven surrogate for improved cardiovascular outcome.
There is no evidence of reversal or prevention of electrocar-
diogram changes or clinical arrhythmia. In the absence of a
proper control group, it is unknown whether the rate of
deterioration is slowed in those patients with most advanced
disease who continue to decline during ERT.35,46 Indeed,
cardiac death is a more common cause of death in patients
with FD than progression to end-stage renal disease.3,47
It is estimated that, depending on the age-range cohort, FD
patients have a 5.5- to 12.2-fold increased risk of stroke
compared to the general population.48 Strokes continue to
occur in patients on ERT.39,49,50 A long-term study from the
UK suggested that stroke occurred more often among patients
older than late 40s undergoing ERT.49 In that study, 19 of 212
patients who were undergoing ERT developed stroke or
transient ischemic attacks, while only 1 of 76 who were not
undergoing ERT developed such complications (P ¼ 0.01,
Fisher’s exact test), possibly suggesting that those patients
with more severe manifestations were receiving ERT. In a
placebo controlled RCT, 2 of 31 patients (6.45%) in the
placebo group and 0 of 51 (0%, P ¼ 0.14) in the agalsidase-b
group experienced a stroke.33 Post hoc analysis of this trial
suggested prevention of new white matter lesions following
ERT compared to placebo.51
Other symptoms. In placebo-controlled RCTs, both agal-
sidase-a and agalsidase-b improved pain scores in adults,52,53
but improvement was also seen in the placebo groups. In
general clinical experience, ERT is only mildly effective at
best35 in decreasing pain, and younger patients may respond
better than do older patients. Improved school attendance has
been reported with ERT.54–56 Patient-reported outcomes from
patient representatives indicate an overall signiﬁcant
improvement of pain in adults and children. A postmarketing
registry paper and other anecdotal evidence suggest
improvement of gastrointestinal symptoms with ERT.57,58
Two studies suggest a beneﬁcial response of ERT on mild-
to-moderate hearing loss,59,60 but a recent longitudinal
analysis demonstrates that hearing loss present before initia-
tion of therapy cannot be reversed.61 Several postmarketing
registry studies suggest improvement of quality of life (QoL)
with ERT. However, the outcome of QoL on ERT is
inconclusive.62287
meet ing repor t R Schiffmann et al.: Fabry disease: a KDIGO conference reportThe issue of dose. The issue of dose has been confounded
by the fact that the label-recommended dose of the 2 available
agalsidase preparations has a 5-fold difference; thus, any
discussion on dose must be interpreted in the context of the
different enzyme preparations. In the absence of adequately
powered RCTs directly comparing 0.2 to 1.0 mg/kg/2 weeks,
individual physicians should evaluate the available placebo-
controlled RCT, case-series, and Canadian FD Initiative
clinical trial results for personalized decision-making
(Supplementary Table S3).
A dose effect, at least in some patients, is suggested for
podocyte Gb3 clearance and preservation of renal function in
case series of repeat kidney biopsy in young patients.
Doubling the frequency of 0.2 mg/kg agalsidase-a in patients
with progressive kidney disease from biweekly to weekly is
also suggested.32,63 The largest randomized, prospective head-
to-head trial comparing agalsidase-a to agalsidase-b in adults
is underpowered but has 5-year longitudinal data on 1.0 mg/
kg/2 weeks agalsidase-b versus 0.2 mg/kg/2 weeks agalsidase-
a with a primary outcome of severe clinical events. There was
no signiﬁcant difference in the event-free survival between the
2 treatment arms. While the hazard ratio of 1.46 favored
agalsidase-b, perhaps reﬂecting differences in baseline char-
acteristics among the 2 patients groups,64 a more recent
analysis of the 8-year data (presented at the Society for the
Study of Inborn Errors of Metabolism meeting in September
2016) reports a hazard ratio of 1.17, which again is not sta-
tistically signiﬁcant despite a patient sample size of 115. While
there is some evidence that higher agalsidase dose results in
better biochemical clearance,65,66 at present there is no evi-
dence to base treatment decisions on biomarker levels that do
not correlate with patient outcomes.67
The limited effect of ERT is likely due to a combination of:
(i) delayed treatment initiation after the onset of irreversible
organ damage; (ii) intermittent administration leaving the
patient with little functional enzyme every second week; (iii)
incomplete tissue penetration of the infused protein; (iv)
presence of anti-agalsidase antibodies; (v) lack of appropri-
ately powered RCTs to detect a very small clinical effect; and
(vi) incompletely understood mechanism of response to
ERT.68 Weekly infusions, a novel a-galactosidase A prepara-
tion with a longer half-life, or the use of small molecules, such
as pharmacological chaperones69 or substrate synthesis
reduction, may address some of these limitations.
Follow-up of treatment. Follow-up recommendations are
listed in Supplementary Table S1. Patients with FD should
have access to coordinated care through expert designated
centers, either through their local physician or by visiting
such a center.
Antibodies develop in a substantial proportion of typical
male FD patients and also in some females, and negatively
inﬂuence known substrate-related biomarkers. Gb3 reac-
cumulation in skin biopsies and greater disease progression
were noted in patients with high antibody titers.70,71
Knowledge gaps and research recommendations
(Table 2). We do not know when ERT should be initiated288and in particular at what age. Is there a cut-off age or disease
stage beyond which beneﬁt of ERT is minimal? These may be
different for different organ systems. The net effect of ERT in
females could also be better ascertained in clinical trials
performed only in female FD patients.NONSPECIFIC STANDARD OF CARE THERAPY
Cardiac and cerebrovascular disease: heart failure, coronary
disease, arrhythmia, and stroke
Cardiac deaths account for the majority of deaths in FD in
both sexes,72,73 and cardiomyopathy has been reported in up
to 90% of patients.74 Low blood pressure is typical.18 Heart
failure may have multifactorial causes that need to be treated
according to general principles beyond ERT. Many patients do
not tolerate b-blockers and may need a pacemaker due to
bradycardia.75 Adjunctive treatment of the cardiac disease
includes renin angiotensin system blockers, which in general
have beneﬁcial effects on regression of hypertrophy.76,77 The
beneﬁcial effect of these drugs is especially well documented
when there is concomitant CKD and hypertension.78 While
chest pain and dyspnea may pose a diagnostic challenge,
coronary disease should be diagnosed and treated similarly to
treatment in non-FD patients.
Cardiac arrhythmias and conduction abnormalities are
frequent, and bradycardia and atrial ﬁbrillation are common
ﬁndings.75 The risk of stroke in patients with paroxysmal
atrial ﬁbrillation, which is often asymptomatic, may be
underestimated, and anticoagulation is needed in many of
these patients.68 The indication is probably stronger than the
general recommendations in the ESC guidelines,79 although
the risk for cerebral microbleeds must be recognized.80
Because both small and large cerebral vessels are involved,
effective antiplatelet agents are highly recommended to
prevent stroke in enzyme-naïve patients and in those un-
dergoing ERT for primary and secondary stroke preven-
tion.81 Implantation of a pacemaker is necessary in cases
with symptomatic and severe bradycardia.82 Malignant ar-
rhythmias are usually associated with occurrence of
replacement ﬁbrosis in advanced hypertrophic cardiomyop-
athy in male patients, and may also be seen in females before
they develop overt left ventricular hypertrophy.83 Implanta-
tion of a cardioverter-deﬁbrillator should be considered in
these patients.84,85Pulmonary disease
Dyspnea is a frequent symptom in many patients, and dif-
ferential diagnosis between disturbed systolic or diastolic
cardiac function versus pulmonary or airway dysfunction may
be difﬁcult. A mixture of different etiologic mechanisms of
obstructive and restrictive pulmonary symptoms has been
reported in several small studies and case reports, and a recent
systematic review could not identify consistent ﬁndings in
the literature.86 A registry study concluded that 23 of 67 pa-
tients had airway obstruction similar to chronic obstructive
pulmonary disease, and obstructive lung disease has beenKidney International (2017) 91, 284–293
R Schiffmann et al.: Fabry disease: a KDIGO conference report mee t ing repor treported to be up to 10 times more prevalent in people with
FD than in the general population.
Neuropathic pain (chronic pain and pain crisis)
Neuropathic pain associated with small ﬁber neuropathy is a
key feature of FD from childhood or early adulthood (average
age of onset is 9 years in males and 16 years in females,
though onset as early as the age of 5 years has been re-
ported).87,88 No RCT has been conducted in the treatment of
neuropathic pain in FD. Tables 3 and 4 show recommended
approaches to treatment of chronic neuropathic pain and
pain crisis in FD.
The mechanisms of FD neuropathy are not fully under-
stood, but evidence of substrate deposits in dorsal root
ganglia, stenosis and occlusion of vasa nervorum, and up-
regulation of ectopic and unstable sodium channels and
TRPV channels as expressions of nerve damage have been
hypothesized to contribute to acroparesthesias and pain cri-
ses.89 Drugs generally have similar efﬁcacy in various condi-
tions, except in trigeminal neuralgia, chronic radiculopathy,
and HIV neuropathy, with level A evidence in support of
tricyclic antidepressants, pregabalin, gabapentin, tramadol,
and opioids (in various conditions) and duloxetine, ven-
lafaxine, topical lidocaine, and capsaicin patches (in restricted
conditions). Combination therapy appears useful for tricyclic
antidepressants, gabapentin, and gabapentin-opioids.90
Sodium-channel blockers (carbamazepine) have been re-
ported to have beneﬁcial effect on gastrointestinal symptoms
as well as emotional (depressive) symptoms.91,92
Renal involvement
Gb3 deposits have been described in many renal cell types as
early as 17 weeks of gestation93 and in placental tissue of pa-
tients with FD.94 Kidney biopsy studies have shown age-
dependent progressive accumulation of Gb3 in podocytes,
and correlations between early kidney damage and albumin-
uria.95 Early treatment with ERTmay help prevent progressive
renal involvement during 5 years of treatment in children with
normoalbuminuria or microalbuminuria.32 A correlation be-
tween the cumulative administered dose of ERT, podocyte
clearance of Gb3, and improvement in albuminuria has been
suggested.32 Importantly, the transition from Gb3 accumula-
tion in podocytes to the earliest phases of injury denoted by
podocyte foot process effacement occurs before there are
clinically evident increases in urinary albumin or proteinTable 3 | Adjunctive therapy for chronic pain
Agent Dose range
Carbamazepine115,116 250–800 mg/d May i
Gabapentin117 Slowly titrated from 100 to a
max of 2400 mg/d
Phenytoin118 300 mg/d
Pregabalin89 75–300 mg/d
Tricyclic antidepressants119 25–150 mg/d
Duloxetine120 60–120 mg /d
Kidney International (2017) 91, 284–293excretion.42 Recently, increased urinary loss of podocytes has
been described early in FD, again before the onset of clinically
apparent proteinuria.43,96 The phases of tissue accumulation of
Gb3, cellular injury, organ damage, and progressive loss of
kidney function are represented in Figure 1.
Generally, the diagnosis of early decline of GFR in patients
with FD and CKD is hampered by inaccuracy of creatinine-
based GFR measurements. Overestimation of true GFR may
be especially relevant in many male FD patients. A measured
GFR (e.g., iohexol GFR) may therefore be helpful in the
assessment of nephropathy.97,98 However, it should be
emphasized that there may be signiﬁcant renal involvement
before any changes in GFR are measured or estimated
(Figure 1).
The mainstay approach for reducing urinary protein and
albumin excretion in all forms of CKD has been the use of
renin angiotensin system blockade with angiotensin-
converting enzyme inhibitors or angiotensin-receptor
blockers, which has also been associated with improved
renal and cardiac outcomes.37 Recognizing the trade-off of
control of proteinuria and the associated reduction in blood
pressure with these agents, the goal for proteinuria reduction
is not clearly deﬁned in any form of CKD. The best available
evidence is based on a meta-analysis of nondiabetic CKD
treated with angiotensin-converting enzyme inhibitors; there
was a clear-cut beneﬁt of ACE inhibition compared to other
forms of hypertension control when urinary protein excretion
exceeded 500 mg/d.99 Renin angiotensin system blockade has
been shown to prevent the transition from microalbuminuria
to overt albuminuria in patients with diabetes, but this effect
was reversed when the therapy was stopped and did not have
a persistent beneﬁcial effect on kidney function.100–102 The
effects of angiotensin-receptor blocker therapy on albumin
excretion can be dissociated from the primary effect on sys-
temic blood pressure, and in post hoc analyses, changes in
urinary albumin excretion have been independently associ-
ated with slowing of progressive loss of renal function.103
Despite these promising ﬁndings, more recent efforts to
prevent microalbuminuria or aggressively control proteinuria
in diabetic kidney disease have been disappointing.104
There is a direct relationship between loss of renal func-
tion and sex, and also with severity of proteinuria both before
and after the initiation of ERT.105–107 A single-center study
reported stabilization of renal function in 6 classic FD pa-
tients at high risk for progression to end-stage renal diseaseCardiac restrictions Renal restrictions
nterfere with activity of other
drugs (e.g., warfarin)
None
None Caution with chronic kidney disease
None None
None Caution with chronic kidney disease
Arrhythmias None
None None
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Table 4 | Adjunctive therapy for pain crisis
Agent Dose range Experience in Fabry disease and side effects Cardiac and renal restrictions
IV lidocaine121 2–5 mg/kg Good clinical response Arrhythmias, no renal restrictions
Tramadol122 100–400 mg/d Caution with concomitant use of
SSRIs, SNRIs, or TCAs
Caution with chronic kidney
disease and epilepsy
Morphine122 Titration of 30–120 mg
every 12 h
Monitor for addiction;
constipation
None
Oxycodone91 Titration of 20–60 mg
every 12 h
Monitor for addiction; constipation None
Diclofenac91 50–150 mg/d Risk of GI bleeding Caution with chronic kidney disease
GI, gastrointestinal; h, hours; IV, intravenous; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
meet ing repor t R Schiffmann et al.: Fabry disease: a KDIGO conference reportwith control of proteinuria to a target of 0.5 g/d while
receiving concurrent ERT at 1 mg/kg every 2 weeks.106 This
study was recognized in the European Renal Best Practice
report, but was not incorporated into the overall recom-
mendations pending conﬁrmation of these ﬁndings in a
larger group of classic FD patients.108 A recent report on a
larger series of 24 patients described successful titration and
maintenance of urinary protein-to-creatinine ratio at 0.5 g/g
with angiotensin-converting enzyme inhibitors or
angiotensin-receptor blockers in 18 of the 24 patients who
completed the 24-month open-label protocol.109 Despite
successful control of proteinuria in these 18 patients, only 6
experienced stabilization of their kidney function, while the
remaining 12 patients continued to lose renal function at the
same rate as the 6 patients who could not achieve the target
for control of proteinuria.109 The only identiﬁed factor that
distinguished the patients who achieved the proteinuria
goal and had preserved renal function from those who did
not have preserved renal function was the age at which ERT
was initiated. Similarly, a 10-year follow-up of the phase 3
agalsidase-b trial39 patients showed that those who started
ERT at a younger age had a signiﬁcantly more favorable
response.Cellular
Injury
Damage
Organ
Damage:
Initiation
of Fibrosis
Organ
Failure
Loss of
Function
Cellular
GL3
Deposits
Burden
of Disease
Stage 2Stage 1 Stage 3 Stage 4
Time (years)
Organ
failure
Tissue
involvement
Cellular GL-3 storage
Figure 1 | Fabry nephropathy: GL3 accumulation, cellular injury,
organ injury, and progressive loss of renal function. Adapted from
Eng et al. with permission.123 ACR, albumin-creatinine ratio; ESRD,
end-stage renal disease; GFR, glomerular ﬁltration rate.
290Individual FD patients should follow the general guidelines
for management of CKD, including blood pressure optimi-
zation, smoking cessation, dietary salt restriction, and man-
agement of hyperlipidemia.37 A kidney biopsy should
deﬁnitely be considered to conﬁrm the diagnosis of Fabry
nephropathy, evaluate the severity of irreversible renal
involvement,30,110 and diagnose superimposed kidney disease
in cases of unexpected kidney ﬁndings.111 Several other
approaches have also been described, including decreasing the
ERT dosing interval,63 the addition of amiloride to the anti-
proteinuric regimen,112 and the addition of paricalcitol
therapy to renin angiotensin system blockade.113 Prospective
evaluations of these approaches with larger numbers of
patients are needed to improve the renal outcomes of patients
with FD.
Knowledge gaps and research recommendations
(Table 2). The biggest challenge is to separate the net
contribution of speciﬁc therapy such as ERT from the overall
effect of the nonspeciﬁc but powerful standard of care in-
terventions described above. Future research should focus on
additional ways to protect the glomerular function of the
kidneys and cardiac rhythm and conduction system. The
latter has thus far not responded to any speciﬁc treatment.
CONCLUSION
FD is a complex multisystem disease with mostly nonspeciﬁc
symptoms and signs. Diagnosis requires a high index of
suspicion in symptomatic patients and screening of certain at-
risk groups. Common standard-of-care therapies are highly
effective in alleviating symptoms and treating disease com-
plications. ERT is the ﬁrst speciﬁc therapy developed that can
slow kidney disease and alleviate symptoms but confers little
beneﬁt to cardiovascular and cerebrovascular outcomes.
Additional speciﬁc therapeutic agents such as modiﬁed a-
galactosidase A with a longer half-life and better tissue
penetration, pharmacological chaperones, and substrate
reduction therapy may further improve patient health.
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